Summary
12.63
0.29
(2.31%)
08/13/2026
Benitec Biopharma Inc. (BNTC)Key Facts
Performance
Historical returns1D
2.31%
1W
-6.02%
1M
-5.00%
3M
4.22%
6M
8.82%
1Y
-0.40%
5Y
-81.67%
Snapshot
Key statisticsClose
12.63
Change
0.29
Change %
2.31%
Open
12.50
Day Range
12.43 – 12.97
Volume
128,697
Avg Vol (20d)
136,579
Rel Vol
0.94x
52W Range
9.85 - 16.76
vs 52W High
-24.67%
vs 52W Low
28.17%
Gap
-0.39
Market Cap
USD 340.21M
Beta
0.18
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
Notable Price Movement
Historical returnsAug 13
2026
$12.63 2.31%Latest
Benitec Biopharma rose 2.31% to $12.63. This was largely stock-specific: the S&P 500 gained 0.64% while Healthcare peers (XLV) rose 0.03% that session, leaving about 2.2 points of the move unexplained by the market after adjusting for a 0.18 beta. Shares opened with a 1.30% gap up. The move left the stock 23.6% below its 52-week high.
Aug 12
2026
$12.34 8.46%
Benitec Biopharma fell 8.46% to $12.34, its biggest one-day drop in 6 months and a 2.6σ move against its 60-day volatility, on 16.7× average volume. This was largely stock-specific: the S&P 500 gained 0.25% while Healthcare peers (XLV) rose 0.26% that session, leaving about 8.5 points of the move unexplained by the market after adjusting for a 0.18 beta. Shares closed near the session low (5% of the day's range).
Aug 4
2026
$12.52 3.05%
Benitec Biopharma rose 3.05% to $12.52. This was largely stock-specific: the S&P 500 gained 1.80% while Healthcare peers (XLV) fell 0.09% that session, leaving about 2.7 points of the move unexplained by the market after adjusting for a 0.18 beta. Shares opened with a 1.48% gap up, closed near the session high (86% of the day's range) and reclaimed their 20- and 200-day moving averages.
Aug 3
2026
$12.15 3.76%
Benitec Biopharma rose 3.76% to $12.15, its biggest one-day gain in 4 weeks. This was largely stock-specific: the S&P 500 gained 1.42% while Healthcare peers (XLV) fell 0.19% that session, leaving about 3.5 points of the move unexplained by the market after adjusting for a 0.18 beta. Shares opened with a 1.37% gap up, closed near the session high (88% of the day's range) and reclaimed their 50-day moving average.
Jul 20
2026
$11.97 6.34%
Benitec Biopharma fell 6.34% to $11.97, its biggest one-day drop in 2 months and a 2.0σ move against its 60-day volatility. This was largely stock-specific: the S&P 500 fell 0.16% while Healthcare peers (XLV) fell 1.14% that session, leaving about 5.2 points of the move unexplained by its sector. Shares opened with a 1.64% gap up and reversed through the session, closed near the session low (4% of the day's range) and lost their 200-day moving average.
Jul 16
2026
$12.66 2.76%
Benitec Biopharma fell 2.76% to $12.66, though on light volume (0.4× the 20-day average). This was largely stock-specific: the S&P 500 fell 0.54% while Healthcare peers (XLV) rose 2.22% that session, leaving about 2.7 points of the move unexplained by the market after adjusting for a 0.18 beta. Shares opened with a 0.77% gap up and reversed through the session and lost their 20-day moving average.
Computed from adjusted closes over the last 22 sessions; attribution vs SPY and XLV.
New Highs
Historical highs| Period | New Highs | From Last |
|---|---|---|
| 5-Day | 1× | -8.38% |
| 1-Month | 4× | -8.38% |
| 3-Month | 5× | -8.38% |
| 6-Month | 4× | -10.33% |
| YTD | 4× | -10.33% |
| Period | New Highs | From Last |
|---|---|---|
| 52-Week | 16× | -23.58% |
| 2-Year | 16× | -24.81% |
| 3-Year | 43× | -24.81% |
| 5-Year | 8× | -82.57% |
| 10-Year | 6× | -98.79% |
Financial SnapshotFY 2025
Full financialsRevenue
n/a
Net Income
-USD 37.92M
+74.3% YoY
EPS
-1.05
-60.8% YoY
Gross Margin
n/a
Operating Margin
n/a
Net Margin
n/a
EBITDA
-USD 41.37M
Free Cash Flow
-USD 23.61M
ROE
-39.0%
ROA
-38.1%
Debt / Equity
0.01x
net debt -USD 96.90M
Cash & Equiv.
USD 97.74M
Fundamental Ratings
MainC+
RecommendedSell
DCFNeutral
ROEStrong Sell
ROAStrong Sell
Debt/EquityBuy
P/EStrong Sell
P/BNeutral
Latest Earnings
- BNTC reported last earnings on 2026-05-14.
- EPS of $-0.24 vs $-0.27 estimated — surprise $0.03.
- Revenue of $0M vs $5M estimated — surprise $-5M.
News
All newsBenitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatment and further improvements in depth of response following treatment with high...
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the first Cohort 1 Patient, and interim clinical results for the first Cohort 2 Patient - BB-301 is...
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA...
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and interim clinical study results for the first Cohort 2 Patient will be reported...
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the...
Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Acquires 50,000 Shares
Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) Director Suvretta Capital Management, L purchased 50,000 shares of Benitec Biopharma stock in a transaction that occurred on Tuesday, December 23rd. The shares were purchased at an average cost of $12.85 per share, with a total value of...
Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Buys 16,836 Shares
Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) Director Suvretta Capital Management, L bought 16,836 shares of the firm's stock in a transaction that occurred on Friday, December 26th. The stock was purchased at an average cost of $13.10 per share, with a total value of $220,551.60....
Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 83.9% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Purchases 10,215 Shares of Stock
Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) Director Suvretta Capital Management, L bought 10,215 shares of the business's stock in a transaction on Thursday, December 18th. The stock was purchased at an average price of $11.24 per share, with a total value of $114,816.60. Following...
Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know
The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 87.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC)
Benitec Biopharma (BNTC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near...
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update
– Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301–
Big Insider Purchases by Carl Icahn, Mario Gabelli, and Others
In the past week or so, beneficial owners Carl Icahn and Mario Gabelli made some big bets in Monro Inc.
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference (“ddRNAi”)...
Benitec Biopharma Inc. Announces Proposed Public Offering
HAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference (“ddRNAi”)...
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA...
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
Investor webcast to be held on Monday November 3, 2025 at 8:00 am EST Investor webcast to be held on Monday November 3, 2025 at 8:00 am EST
Benitec Biopharma Limited (NASDAQ:BNTC) Given Consensus Rating of “Moderate Buy” by Analysts
Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine analysts that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, six have assigned a buy...
Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update
Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of the First Subject into Cohort 2 of the BB-301 Phase 1b/2a Treatment Study Expected in Q4 2025 HAYWARD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc....